Register update: there will be a delay adding new records during our holiday period (Dec 17 - Jan 4)
Cochrane COVID-19 Study Register
Study record
Balushi 2022First Published: 2022 May 13Updated Date: 2022 May 13

COVID-19 Associated Mucormycosis: opportunistic Fugal Infection. A case series and review

  1. Study Type
  2. Observational
  1. Study Aim
  2. Diagnostic/Prognostic
  1. Study Design
  2. Case series/Case control/Cohort
  1. Intervention Assignment
  2. Not Applicable
Reference record

COVID-19 Associated Mucormycosis: opportunistic Fugal Infection. A case series and review

Balushi AA, Ajmi AA, Sinani QA, Menon V, Berieki ZA, Shezawi AA, Azri SA, Rashdi AA, Jardani AA, Baluki TA, Ghaithi SA, Reesi AA, Al-Za'abi AT, Al' Balushi MA, Maqbali TA
Journal article
Report Results
BACKGROUND: A surge in COVID-19 associated mucormycosis cases has been observed during the second COVID-19 wave, in summer 2021. The majority of cases were reported from India. The Delta variant (B.1.617.2) was the most common variant circulating at that time. Mucormycosis is an angio-invasive fungal opportunistic infection with high morbidity and mortality. CASE PRESENTATION: We present 10 cases of COVID-19 associated Rhino-orbital and rhino-orbital-cerebral mucormycosis managed in a secondary hospital in Oman. The median time for developing mucormycosis was two weeks from the COVID-19 diagnosis. All patients were known or newly diagnosed with to have poorly controlled diabetes mellitus. Five patients received corticosteroid therapy for COVID-19. Three patients had severe COVID-19 infection and died due to severe ARDS and septic shock. Another three patients died with advanced mucormycosis and cerebral involvement. Despite aggressive medical and surgical intervention, the mortality rate was 60% (6/10). CONCLUSION: Mucormycosis is an aggressive opportunistic infection with high morbidity and mortality that requires prompt recognition and urgent intervention. Uncontrolled blood sugar, the use of corticosteroids and immune dysfunction due to COVID-19 patients and uncontrolled blood sugar, all are important risk factors for development of mucormycosis. Worse outcomes are associated with poor glycemic control despite aggressive medical and surgical interventions